Skip to main content
Premium Trial:

Request an Annual Quote

Sirna Therapeutics Sees Revenues Dwindle, Losses Widen in Q1

NEW YORK, April 29 (GenomeWeb News) - Sirna Therapeutics reported decreased revenues and widening losses for the first quarter on Tuesday.


Revenues for the quarter totaled $318,000, down from $490,000 for the year-ago period.


R&D expenses for the first quarter were $5.1 million, up from $3.8 million during the same quarter last year.


The company's net loss was $5.9 million, or $.19 per share, up from $4.9 million, or $1.62 per share, for the same period last year.


As of March 31, Sirna, based in Boulder, Colo., had $29.6 million in cash, cash equivalents, and securities.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.